Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.

Little is known about the impact of racial differences on the use of first-line therapies and clinical outcomes; however, African American/Black (AA) patients are grossly underrepresented in all advanced RCC trials. This retrospective chart review looked at the clinical treatment of 95 AA and 378 White American (WA) patients with intermediate/poor-risk aRCC and found that fewer AA patients were treated with standard of care immune-oncology–based therapy vs WA patients, which could impact therapy discontinuation and survival outcomes.